Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Tali FDA Approval on Track for Feb'12
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.38 +1.28%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX) price target of $8.00.
Canaccord analyst, Ritu Baral, said, "We see good chance of Feb. 2012 taliglucerase US approval, Q2/12 US launch and EU approval. We think PLX’s reply to the Feb ‘11 taliglucerase (tali) CRL for Gaucher’s supports full approval on the new Feb’12 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market with competitive pricing."
For more ratings news on Protalix BioTherapeutics click here and for the rating history of Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $5.28 yesterday.
Canaccord analyst, Ritu Baral, said, "We see good chance of Feb. 2012 taliglucerase US approval, Q2/12 US launch and EU approval. We think PLX’s reply to the Feb ‘11 taliglucerase (tali) CRL for Gaucher’s supports full approval on the new Feb’12 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market with competitive pricing."
For more ratings news on Protalix BioTherapeutics click here and for the rating history of Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $5.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Pop Mart International Group Ltd (9992:HK) to Underweight
- Jefferies Downgrades Pop Mart International Group Ltd (9992:HK) to Hold
- NetEase.com (NTES) PT Raised to $168 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
